X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs SANOFI INDIA - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA SANOFI INDIA ASTRAZENECA PHARMA/
SANOFI INDIA
 
P/E (TTM) x 156.2 39.6 394.6% View Chart
P/BV x 24.3 8.5 284.1% View Chart
Dividend Yield % 0.0 1.1 -  

Financials

 ASTRAZENECA PHARMA   SANOFI INDIA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
SANOFI INDIA
Dec-16
ASTRAZENECA PHARMA/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs1,2854,560 28.2%   
Low Rs6344,400 14.4%   
Sales per share (Unadj.) Rs189.61,028.5 18.4%  
Earnings per share (Unadj.) Rs-0.2129.0 -0.2%  
Cash flow per share (Unadj.) Rs3.8186.0 2.1%  
Dividends per share (Unadj.) Rs068.00 0.0%  
Dividend yield (eoy) %01.5 0.0%  
Book value per share (Unadj.) Rs68.6753.6 9.1%  
Shares outstanding (eoy) m25.0023.03 108.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.14.4 116.2%   
Avg P/E ratio x-4,712.734.7 -13,566.0%  
P/CF ratio (eoy) x249.624.1 1,036.1%  
Price / Book Value ratio x14.05.9 235.2%  
Dividend payout %052.7 0.0%   
Avg Mkt Cap Rs m23,988103,174 23.2%   
No. of employees `0001.63.6 43.0%   
Total wages/salary Rs m1,6053,592 44.7%   
Avg. sales/employee Rs Th3,040.26,537.7 46.5%   
Avg. wages/employee Rs Th1,029.2991.4 103.8%   
Avg. net profit/employee Rs Th-3.3819.8 -0.4%   
INCOME DATA
Net Sales Rs m4,74023,686 20.0%  
Other income Rs m92708 13.0%   
Total revenues Rs m4,83224,394 19.8%   
Gross profit Rs m-1305,281 -2.5%  
Depreciation Rs m1011,313 7.7%   
Interest Rs m015 0.0%   
Profit before tax Rs m-1394,661 -3.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1390-   
Tax Rs m51,691 0.3%   
Profit after tax Rs m-52,970 -0.2%  
Gross profit margin %-2.722.3 -12.3%  
Effective tax rate %-3.736.3 -10.1%   
Net profit margin %-0.112.5 -0.9%  
BALANCE SHEET DATA
Current assets Rs m2,72615,673 17.4%   
Current liabilities Rs m2,4356,678 36.5%   
Net working cap to sales %6.138.0 16.2%  
Current ratio x1.12.3 47.7%  
Inventory Days Days7476 97.0%  
Debtors Days Days4122 182.7%  
Net fixed assets Rs m1,0358,098 12.8%   
Share capital Rs m50230 21.7%   
"Free" reserves Rs m94217,088 5.5%   
Net worth Rs m1,71617,356 9.9%   
Long term debt Rs m00-   
Total assets Rs m4,15625,400 16.4%  
Interest coverage xNM311.7-  
Debt to equity ratio x00-  
Sales to assets ratio x1.10.9 122.3%   
Return on assets %-0.111.8 -1.0%  
Return on equity %-0.317.1 -1.7%  
Return on capital %026.9 0.0%  
Exports to sales %5.724.5 23.3%   
Imports to sales %6.528.0 23.1%   
Exports (fob) Rs m2705,801 4.7%   
Imports (cif) Rs m3066,627 4.6%   
Fx inflow Rs m3757,145 5.2%   
Fx outflow Rs m4706,846 6.9%   
Net fx Rs m-96299 -32.0%   
CASH FLOW
From Operations Rs m-83,226 -0.3%  
From Investments Rs m-146-1,555 9.4%  
From Financial Activity Rs m862-1,818 -47.4%  
Net Cashflow Rs m709-147 -482.0%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 60.4 124.2%  
Indian inst/Mut Fund % 0.3 14.4 2.1%  
FIIs % 15.7 14.6 107.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 10.5 86.7%  
Shareholders   12,856 15,184 84.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   ORCHID PHARMA LTD  CIPLA  JUBILANT LIFE SCIENCES  VENUS REMEDIES  STERLING BIOTECH  

Compare ASTRAZENECA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Down 1%; Realty, Auto Stocks Tank(12:30 pm)

After opening the day flat share markets in India are trading on a negative note and are presently trading below the dotted line.

Related Views on News

BIOCON LTD at All Time High; BSE HEALTHCARE Index Down 0.2% (Market Updates)

Sep 24, 2018 | Updated on Sep 24, 2018

BIOCON LTD share price has hit an all time high at Rs 696 (up 1.4%). The BSE HEALTHCARE Index is down by 0.2%. Among the top gainers in the BSE HEALTHCARE Index today are BIOCON LTD (up 1.4%) and SANOFI INDIA (up 2.6%). The top losers include TORRENT PHARMA (down 0.1%) and AUROBINDO PHARMA (down 0.2%).

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 10.3% (Quarterly Result Update)

Aug 21, 2018 | Updated on Aug 21, 2018

For the quarter ended June 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 64 m (up 10.3% YoY). Sales on the other hand came in at Rs 2 bn (up 25.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Sep 24, 2018 01:49 PM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA - VENUS REMEDIES COMPARISON

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS